Compare MTEK & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MTEK | HIND |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Israel | United States |
| Employees | 14 | 18 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 13.8M |
| IPO Year | N/A | 2016 |
| Metric | MTEK | HIND |
|---|---|---|
| Price | $1.15 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 104.3K | 22.2K |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.75 |
| 52 Week High | $4.27 | $12.87 |
| Indicator | MTEK | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 35.76 |
| Support Level | $1.08 | $1.75 |
| Resistance Level | $1.50 | $2.36 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.22 | 13.03 |
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.